Regulatory investigation closed

RNS Number : 2381A
Accrol Group Holdings PLC
20 January 2020
 

 

20 January 2020

 

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.  Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

 

Accrol Group Holdings plc

("Accrol" or the "Company")

 

Regulatory Investigation Closed

 

Further to Accrol's announcements dated 21 January 2019 (RNS number 6698N) and 27 March 2019 (RNS number 1694U) notifying the market of an FCA investigation into the Company, Accrol is pleased to  announce that the FCA has notified it that the FCA has closed its investigation and will not be taking any action.

 

For further information, please contact:

 

 

 

Accrol Group Holdings plc

 

Dan Wright, Executive Chairman

Tel: +44 (0) 1254 278 844

Gareth Jenkins, Chief Executive Officer

 

 

 

Zeus Capital Limited (Nominated Adviser & Broker) 

 

Dan Bate / Andrew Jones            

Tel: +44 (0) 161 831 1512

Dominic King / John Goold

Tel: +44 (0) 203 829 5000



Belvedere Communications Limited

 

Cat Valentine (cvalentine@belvederepr.com)

Tel: +44 (0) 7715 769 078

Keeley Clarke (kclarke@belvederepr.com)

Tel: +44 (0) 7967 816 525

 

Notes to Editors

 

Accrol Group Holdings plc, based in Lancashire, is a leading tissue converter and supplier of toilet rolls, kitchen rolls and facial tissues, as well as other tissue products, to major discounters and grocery retailers throughout the UK. 

 

The business operates from four sites in Lancashire:

 

·

A manufacturing, storage and distribution facility in Blackburn;

·

A storage and administrative centre in Blackburn;

·

A facial tissue plant, also in Blackburn; and

·

A manufacturing, storage and distribution facility in Leyland.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FURBLMFTMTIBBIM
UK 100